Syncor's mid-year results improve
Radiopharmacy firm Syncor International reported improving marginson the strength of continued sales growth through the first halfof 1995. Net sales for the six months ended June 30 increased6.1%, to $166.3 million. Net income for the period was $2.3
Radiopharmacy firm Syncor International reported improving marginson the strength of continued sales growth through the first halfof 1995. Net sales for the six months ended June 30 increased6.1%, to $166.3 million. Net income for the period was $2.3 million,compared to $2.8 million in the first half of 1994.
In the second quarter of 1995, net sales increased 1.7% to $83.3million. Net income for the second quarter was $1.3 million, comparedto $700,000 for the same period last year.
Results through June put the company on track to meet Syncor's1995 financial objectives, according to chief executive Gene McGrevin.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
